OS Therapies, Inc. (OSTX)
1.00
+0.02
(+2.03%)
USD |
NYAM |
Nov 06, 16:00
0.9355
-0.06
(-6.45%)
After-Hours: 20:00
OS Therapies Enterprise Value : 46.15M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 46.15M |
| November 05, 2026 | 45.25M |
| November 04, 2026 | 52.94M |
| November 03, 2026 | 53.39M |
| November 02, 2026 | 52.94M |
| October 30, 2026 | 57.02M |
| October 29, 2026 | 59.73M |
| October 28, 2026 | 57.47M |
| October 27, 2026 | 56.56M |
| October 26, 2026 | 55.66M |
| October 23, 2026 | 57.47M |
| October 22, 2026 | 57.47M |
| October 21, 2026 | 58.38M |
| October 20, 2026 | 57.92M |
| October 19, 2026 | 58.38M |
| October 16, 2026 | 60.64M |
| October 15, 2026 | 64.71M |
| October 14, 2026 | 63.81M |
| October 13, 2026 | 66.53M |
| October 12, 2026 | 71.51M |
| October 09, 2026 | 74.22M |
| October 08, 2026 | 74.22M |
| October 07, 2026 | 71.05M |
| October 06, 2026 | 68.34M |
| October 05, 2026 | 73.32M |
| Date | Value |
|---|---|
| October 02, 2026 | 74.22M |
| October 01, 2026 | 73.77M |
| September 30, 2026 | 73.32M |
| September 29, 2026 | 73.77M |
| September 28, 2026 | 75.58M |
| September 25, 2026 | 76.04M |
| September 24, 2026 | 76.04M |
| September 23, 2026 | 75.58M |
| September 22, 2026 | 81.02M |
| September 21, 2026 | 79.66M |
| September 18, 2026 | 81.02M |
| September 17, 2026 | 83.73M |
| September 16, 2026 | 80.11M |
| September 15, 2026 | 81.47M |
| September 14, 2026 | 77.85M |
| September 11, 2026 | 76.94M |
| September 10, 2026 | 83.28M |
| September 09, 2026 | 85.09M |
| September 08, 2026 | 83.73M |
| September 04, 2026 | 86.00M |
| September 03, 2026 | 83.28M |
| September 02, 2026 | 78.30M |
| September 01, 2026 | 76.04M |
| August 31, 2026 | 77.39M |
| August 28, 2026 | 75.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.632M |
| Total Expenses (Quarterly) | 8.632M |
| EPS Diluted (Quarterly) | -0.1966 |
| Earnings Yield | -104.3% |
| Normalized Earnings Yield | -104.34 |